Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
431. |
ECCT/17/03/05 | HOPE Sickle Cell Disease Clinical Study A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease |
Principal Investigator(s) 1. Videlis Nduba 2. Jessie Nyokabi Githanga Site(s) in Kenya 1. Gertrude\'s Children\'s Hospital (Nairobi City county) 2. Strathmore University Medical Center (Nairobi City county) 3. KEMRI CRDR Clinical Research clinic at Chandaria Health Center (Nairobi City county) 4. KEMRI Kondele Childrens Hospital Center for Clinical Research (Kisumu county) 5. KEMRI Clinical Research Center at Siaya County Referral Hospital (Siaya county) |
14-07-2017 |
View |
432. |
ECCT/17/03/01 | The POWER cohort A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women |
Principal Investigator(s) 1. Dr. Stella Njuguna Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county) |
04-05-2017 |
View |
433. |
ECCT/17/08/04 | P1081 A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: NICHD P1081 |
Principal Investigator(s) 1. FREDRICK KIPYEGON SAWE Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre. |
13-11-2017 |
View |
434. |
ECCT/17/05/01 | Multicenter Study of the Accuracy of the BD MAXâ„¢MDR-TB Assay Multicenter Study of the Accuracy of the BD MAX™MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid |
Principal Investigator(s) 1. SAMUEL GURRION OUMA Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITIUTE |
20-08-2017 |
View |
435. |
ECCT/17/05/03 | TDF IVR-002 Study Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya Partners in Health Research & Development (Thika Partners Clinical Trial Site) |
18-07-2017 |
View |
436. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
10-01-2017 |
View |
437. |
ECCT/16/12/01 | The Partners Scale-Up Project Animplementation project to scale-up delivery of antiretroviral-based HIV-1 prevention amongKenyan HIV-1 serodiscordant couples. |
Principal Investigator(s) 1. Prof. Elizabeth Ann Bukusi Site(s) in Kenya 1. KISUMU SITE (Kisumu county) 2. Thika Site (Kiambu county) |
13-02-2017 |
View |
438. |
ECCT/16/12/03 | The Partners Scale-Up Project An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention among Kenyan HIV-1 serodiscordant couples |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. Thika Level 5 Hospital, Ruiru Sub-County Hospital, Kiambu County Hospital, Kikuyu PCEA Hospital (Kiambu county) 2. Coptic Hospital, Mbagathi Hospital, St. Mary\'s Hospital, Pumwani Maternity Hospital (Nairobi City county) 3. Nyeri PGH, Karatina Sub-County Hospital, (Nyeri county) 4. Kerugoya County Hospital (Kirinyaga county) 5. Murang\'a County Hospital (Murang\'a county) |
04-02-2017 |
View |
439. |
ECCT/17/03/03 | FLACSAM First Line Antimicrobials in Children with Complicated Severe Acute Malnutrition |
Principal Investigator(s) 1. James Berkley Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Coast General Hospital (Mombasa county) 3. Mbagathi Hospital (Nairobi City county) |
21-06-2017 |
View |
440. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |